News|Webcasts|March 3, 2025

FSP Outsourcing Trends and Opportunities

Webinar Date/Time: Tuesday, April 1, 2025 at 11:00 AM EST

Join experts from PPD FSP solutions as they discuss the latest FSP trends and opportunities in clinical development, innovative FSP strategies and models, and keys to successfully leveraging an FSP model to drive on-time and on-budget delivery.

Register Free: https://www.appliedclinicaltrialsonline.com/act_w/fsp-outsourcing-trends
Event overview
Join experts from PPD FSP solutions—part of the PPD clinical research business of Thermo Fisher Scientific—as they discuss the latest utilization and growth projections of FSP partnerships in the clinical research and development landscape, innovative FSP strategies to address drug development challenges and opportunities, and keys to successfully leveraging an FSP model to drive on-time and on-budget delivery.

Key Learning Objectives

Understand the latest utilization and growth projection of FSP partnerships in the clinical research and development landscape
Learn about innovative FSP strategies and models to address drug development challenges and opportunities
Identify the keys to successfully leveraging an FSP model to drive on-time, on-budget delivery

Who Should Attend
Biopharma and biotech company employees involved in:

Clinical development
- Biostatistics and programming
- Clinical data management
- Clinical development
- Clinical operations
- Clinical monitoring
- Clinical research
- Clinical supplies
- Medical affairs
- Medical writing
- Pharmacovigilance
- Project delivery
- Quality assurance/control
- Regulatory affairs
- Sites & patients
- Study start up
- Therapeutic area leads
Business services
- Alliance management/partnering
- Finance
- Procurement
- Purchasing
- Vendor management

Speakers:

Lori Boyce
Vice President
PPD FSP Solution

Lori Boyce has more than 25 years of experience in the field of clinical research and more than 18 years of experience in clinical operations. She has a broad range of experience working with clients to identify innovative solutions to operational and strategic priorities.

Mike Lydon
Director
PPD FSP Solutions

Mike Lydon has more than 16 years of experience within the clinical research industry and has held various leadership roles within the FSP sales and talent resourcing space for top clinical research organizations. His consultative approach to partnerships helps his customers practice innovation, accelerate quality, and reduce burdens.

Register Free: https://www.appliedclinicaltrialsonline.com/act_w/fsp-outsourcing-trends

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

September 4th, 2026

The Unquantified Value of RBQM: Reduced Rework, Data Integrity, and Inspection Readiness

In this video interview, Sylviane de Viron of CluePoints and Abigail Dirks of Tufts CSDD discuss what the RBQM financial model left out—reduced rework, improved data integrity, and inspection readiness—and why those excluded factors could represent even greater value than what was modeled.

© JHVEPhoto - © JHVEPhoto - stock.adobe.com

September 16th, 2026

FDA Opens Applications for Expedited IND Pilot Designed to Accelerate First-in-Human Trial Timelines

The pilot pairs drug sponsors with qualified research institutions to compress the path from drug identification to first-in-human study through rolling submission review and earlier coordination of institutional review board and site activation activities.

This article summarizes the FDA's four-part Patient-Focused Drug Development (PFDD) guidance series, the parallel mechanisms emerging in the European Union and the United Kingdom, the operational gaps sponsors most often encounter, and the areas in which large-scale, structured, patient-reported real-world data can and cannot contribute to a PFDD-aligned research plan. Credit: Stock.Adobe.com/Bordinthorn.

September 16th, 2026

Operationalizing the Patient Voice: Converging U.S., EU, and UK Requirements and the Role of Real-World Patient-Reported Data

Regulatory expectations for patient input in drug development have shifted from aspiration to documented methodology across three major jurisdictions.

September 16th, 2026

The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data

This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.

September 14th, 2026

The Execution Gap: Why Clinical Trial Infrastructure Has to Be Built Before AI Can Deliver

Clinical trials have spent decades perfecting data capture, but the execution layer underneath it, including decision workflows, data collection design, and lab connectivity, remains fragmented in ways that limit what AI can realistically deliver and that quietly compromise the scientific validity of the data itself.

September 11th, 2026

Why Seizure Counts Alone Can't Define Success in Epilepsy Trials

In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why the full burden of developmental and epileptic encephalopathies extends far beyond clinical symptoms—and why endpoints must reflect what families are actually hoping for.

© putilov_denis - © putilov_denis - stock.adobe.com

September 9th, 2026

From Participation to Understanding: Reframing Engagement in Clinical Trials

Participant engagement depends more on clarity and understanding than on gamification or incentives, requiring engagement embedded into trial workflows as a core design component rather than a peripheral consideration

September 8th, 2026

What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale

In this video interview, Sylviane de Viron of CluePoints and Abigail Dirks of Tufts CSDD explain how ICH E6(R3) and new empirical evidence of RBQM's net financial impact give sponsors the tools they need to build the multi-functional buy-in required for successful adoption—and why RBQM only delivers full value when it replaces, not supplements, traditional monitoring.